Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.
| Author | |
|---|---|
| Abstract |
:
Myelodysplastic syndromes are characterised by ineffective erythropoiesis leading to anaemia. Sotatercept (ACE-011) is a novel activin receptor type IIA fusion protein that acts as a ligand trap to neutralise negative regulators of late-stage erythropoiesis. The aim of the study was to establish a safe and effective dose of sotatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes. |
| Year of Publication |
:
2018
|
| Journal |
:
The Lancet. Haematology
|
| Date Published |
:
2018
|
| URL |
:
http://linkinghub.elsevier.com/retrieve/pii/S2352-3026(18)30002-4
|
| DOI |
:
10.1016/S2352-3026(18)30002-4
|
| Short Title |
:
Lancet Haematol
|
| Download citation |
